Your browser is no longer supported. Please, upgrade your browser.
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own0.40% Shs Outstand183.21M Perf Week-4.44%
Market Cap14.36B Forward P/E181.66 EPS next Y0.47 Insider Trans-1.23% Shs Float182.54M Perf Month8.91%
Income-45.70M PEG- EPS next Q0.08 Inst Own97.50% Short Float5.55% Perf Quarter2.47%
Sales1.85B P/S7.77 EPS this Y117.90% Inst Trans0.32% Short Ratio7.05 Perf Half Y11.56%
Book/sh23.29 P/B3.71 EPS next Y355.60% ROA0.30% Target Price113.74 Perf Year9.64%
Cash/sh6.49 P/C13.30 EPS next 5Y32.16% ROE0.40% 52W Range71.59 - 92.57 Perf YTD-1.60%
Dividend- P/FCF78.86 EPS past 5Y15.10% ROI0.20% 52W High-6.78% Beta0.51
Dividend %- Quick Ratio3.00 Sales past 5Y15.90% Gross Margin74.20% 52W Low20.53% ATR2.44
Employees3059 Current Ratio4.50 Sales Q/Q-14.30% Oper. Margin-3.30% RSI (14)58.06 Volatility2.74% 2.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-146.10% Profit Margin0.90% Rel Volume2.42 Prev Close87.40
ShortableYes LT Debt/Eq0.25 EarningsOct 27 AMC Payout0.00% Avg Volume1.44M Price86.29
Recom1.80 SMA202.12% SMA508.14% SMA2008.94% Volume3,478,973 Change-1.27%
Nov-22-21Upgrade William Blair Mkt Perform → Outperform
Oct-07-21Resumed Jefferies Buy $100
Sep-09-21Upgrade Stifel Hold → Buy $86 → $96
Jun-04-21Resumed Robert W. Baird Outperform $101
Apr-26-21Resumed Credit Suisse Outperform $102
Mar-04-21Resumed Guggenheim Buy
Mar-01-21Upgrade Evercore ISI In-line → Outperform $90 → $100
Aug-20-20Downgrade William Blair Outperform → Mkt Perform
Aug-20-20Downgrade Citigroup Buy → Neutral $148 → $86
Aug-19-20Downgrade Stifel Buy → Hold $127 → $100
Aug-19-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
Nov-30-21 09:35PM  
08:07PM  
07:56PM  
06:22PM  
06:18PM  
11:56AM  
10:00AM  
08:45AM  
08:00AM  
Nov-29-21 09:23PM  
04:44PM  
02:29PM  
11:15AM  
09:45AM  
08:30AM  
06:32AM  
05:00AM  
Nov-28-21 02:01PM  
11:15AM  
11:00AM  
08:37AM  
Nov-27-21 10:03PM  
01:00PM  
Nov-26-21 10:07AM  
Nov-25-21 06:42PM  
11:00AM  
Nov-24-21 06:11PM  
03:48PM  
03:16PM  
11:45AM  
11:21AM  
11:02AM  
10:00AM  
04:27AM  
Nov-23-21 03:24PM  
Nov-22-21 10:00PM  
06:30PM  
06:03PM  
03:15PM  
02:13PM  
11:23AM  
09:25AM  
07:55AM  
Nov-21-21 10:32AM  
08:37AM  
Nov-20-21 10:40PM  
10:00PM  
08:00AM  
Nov-19-21 07:34PM  
05:48PM  
04:23PM  
03:55PM  
03:30PM  
03:14PM  
12:38PM  
11:15AM  
11:03AM  
11:02AM  
10:42AM  
10:00AM  
09:59AM  
08:30AM  
06:49AM  
Nov-18-21 08:10PM  
06:42PM  
06:28PM  
05:54PM  
04:55PM  
03:55PM  
03:12PM  
09:53AM  
08:25AM  
Nov-17-21 07:15PM  
06:12PM  
06:08PM  
04:46PM  
03:10PM  
12:38PM  
11:00AM  
09:45AM  
08:40AM  
Nov-16-21 10:38PM  
09:00PM  
06:40PM  
06:02PM  
03:55PM  
03:08PM  
09:30AM  
08:40AM  
Nov-15-21 04:34PM  
03:08PM  
11:30AM  
11:00AM  
10:00AM  
08:30AM  
08:30AM  
Nov-14-21 11:00AM  
10:24AM  
Nov-13-21 09:20PM  
12:15PM  
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 26Sale73.602,739201,59055,853Oct 28 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 20Option Exercise37.461,00037,460305,839Oct 22 04:36 PM
Davis George EricEVP, General CounselAug 02Sale76.695,518423,17558,590Aug 04 04:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 21Option Exercise37.461,00037,460304,839Jun 23 05:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Option Exercise26.498,513225,509312,352May 12 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale77.298,513657,970303,839May 12 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Option Exercise26.4925,000662,250328,839May 10 09:07 PM
Mueller BrianEVP, Chief Financial OfficerMay 07Option Exercise28.236,709189,39538,066May 11 07:42 PM
Mueller BrianEVP, Chief Financial OfficerMay 07Sale79.506,709533,36631,357May 11 07:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Sale78.1225,0001,953,121303,839May 10 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Option Exercise26.4925,000662,250328,839May 10 09:07 PM
MEIER RICHARD ADirectorMay 06Option Exercise26.4915,000397,35099,340May 07 07:48 PM
MEIER RICHARD ADirectorMay 06Sale78.385,068397,24594,272May 07 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Sale78.2925,0001,957,199303,839May 10 09:07 PM
Davis George EricEVP, General CounselMay 03Sale78.304,673365,89664,108May 04 08:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 30Option Exercise37.461,00037,460303,498May 03 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Option Exercise26.4910,000264,900312,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Sale79.3410,000793,400302,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 22Option Exercise26.4910,000264,900312,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 22Sale78.9110,000789,100302,498Apr 26 08:44 PM
Davis George EricEVP, General CounselApr 19Option Exercise26.492,70971,76171,149Apr 20 09:53 PM
Davis George EricEVP, General CounselApr 19Sale79.582,709215,58268,440Apr 20 09:53 PM
LAWLIS V BRYANDirectorApr 15Option Exercise26.497,500198,67526,350Apr 19 04:09 PM
LAWLIS V BRYANDirectorApr 15Sale76.907,500576,75018,850Apr 19 04:09 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 08Sale78.811,537121,13158,250Apr 09 05:57 PM
Mueller BrianEVP, Chief Financial OfficerApr 01Sale76.305,692434,30031,016Apr 02 07:35 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 24Sale76.301,18190,11061,439Mar 26 05:45 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 18Sale77.991,308102,01164,133Mar 19 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Option Exercise26.497,000185,430302,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Sale77.107,000539,700295,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise26.497,000185,430302,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale77.687,000543,760295,652Mar 15 08:26 PM
GREY MICHAEL GDirectorMar 05Option Exercise26.495,000132,45047,840Mar 09 05:59 PM
GREY MICHAEL GDirectorMar 05Sale76.285,000381,40042,840Mar 09 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Option Exercise26.497,000185,430302,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Sale83.587,000585,060295,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Option Exercise26.497,000185,430302,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Sale85.087,000595,560295,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Option Exercise26.498,000211,920303,552Feb 18 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Sale84.548,000676,320295,552Feb 18 09:45 PM
LAWLIS V BRYANDirectorFeb 16Option Exercise26.497,500198,67526,350Feb 18 06:43 PM
LAWLIS V BRYANDirectorFeb 16Sale87.417,500655,57518,850Feb 18 06:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Option Exercise26.498,334220,768303,886Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Sale82.678,334688,972295,552Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 28Option Exercise26.498,333220,741303,885Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 28Sale82.918,333690,889295,552Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 27Option Exercise26.498,333220,741303,885Jan 28 07:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 27Sale85.498,333712,388295,552Jan 28 07:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale88.181,500132,270295,552Dec 30 08:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale88.771,500133,155297,052Dec 30 08:02 PM